Welcure Drugs & Pharmaceuticals logo

Welcure Drugs & Pharmaceuticals financials: balance sheet, profit and loss, cash flow

BSE: 524661Pharmaceuticals & BiotechnologySmall Cap

Welcure Drugs & Pharmaceuticals ltd · Face value ₹1 · Listed Oct 1994
Last close ₹0.18₹0.00 (0.00%)

Share price at the BSE close on 30 Oct 2026. Previous close ₹0.18.

30 Oct: open ₹0.18, high ₹0.19, low ₹0.17

52-week range of traded prices to 30 Oct 2026
₹0.17Low, 23 Oct 2026₹0.64High, 13 Nov 2025
Market cap
₹22 Cr3,646th largest listed
P/E
No recent results
P/B
No recent results
Dividend yield
Nonein the last 12 months
Volume, BSE
86,46,796

Welcure Drugs & Pharmaceuticals' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.Welcure Drugs & Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
0.10.0Mar 170.10.0Mar 180.10.00Mar 190.10.00Mar 200.10.10Mar 210.10.00Mar 2200.10Mar 230−0.20Mar 24Mar 25366−5.50Mar 26
Peak revenue ₹366 Cr, year to Mar 2026; lowest ₹0.00 Cr, year to Mar 2023A loss in 4 of the 9 years with results on record

Operating and net margin, per cent

  • Operating margin
  • Net margin
41.3%−38.0%2.9%−11.9%41.2%22.5%−1.9%31.1%−38.0%4.9%−11.5%41.3%22.5%−1.5%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue366
  2. Materials and goods−322
  3. Employee costs−0.1
  4. Other expenses−50
  5. Operating profit−6.9
  6. Depreciation0.0
  7. Other income+1.5
  8. One-off items0.0
  9. Finance costs0.0
  10. Profit before tax−5.5
  11. Tax0.0
  12. Net profit−5.5

What the company owns

  • Receivables₹213 Cr
  • Plant, investments and other assets₹153 Cr
  • Inventory₹144 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Other liabilities₹413 Cr
  • Net worth₹97 Cr

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the year to Mar 2025.Welcure Drugs & Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Revenue from operations00000000–366
––000000–372
Materials and goods bought––000000–322
Employee costs––000000–0
Other expenses––000000–50
Operating profit before depreciation––000000–−7
Operating margin––2.9%−11.9%41.2%22.5%–––−1.9%
Materials, % of revenue––0.0%0.0%0.0%0.0%–––88.2%
Employee costs, % of revenue––5.3%10.2%6.3%12.3%–––0.0%
Other expenses, % of revenue––91.8%101.7%52.5%65.2%–––13.7%
Depreciation and amortisation––000000–0
Operating profit after depreciation––000000–−7
Other income–0000000–1
Finance costs––000000–0
One-off items––000000–0
Profit before tax00000000–−5
Tax––000000–0
Net profit00000000–−5
Net margin31.1%−38.0%4.9%−11.5%41.3%22.5%–––−1.5%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2017 and Mar 2018: the statement does not state its finance costs or depreciation, which operating profit is worked out from, so operating profit is not given.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations25.519.31.50.9–0.00.00.10.1
27.624.32.21.5–––––
Materials and goods bought20.615.4–––––––
Employee costs–1.4–1.0–––––
Other expenses–7.4–0.5–––––
Operating profit before depreciation−2.1−4.9−0.7−0.6–––––
Operating margin−8.1%−25.5%−47.7%−72.8%–––––
Materials, % of revenue–79.5%–––––––
Employee costs, % of revenue–7.0%–113.8%–––––
Other expenses, % of revenue–38.5%–54.5%–––––
Depreciation and amortisation0.40.40.40.4–––––
Operating profit after depreciation−2.5−5.4−1.1−1.0–––––
Other income1.10.20.12.20.20.00.0–0.1
Finance costs0.51.40.80.0–––––
Profit before tax−1.9−6.6−1.81.1−0.10.00.00.00.1
Tax0.00.0–––––––
Net profit−2.0−6.6−1.81.1−0.10.00.00.00.1
Net margin−7.7%−34.2%−119.5%129.9%–36.7%7.9%11.3%86.0%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
000021–97
Share capital121212121313–124
Reserves−12−12−12−12−12−12–−27
Borrowings000000–0
000000–214
000000–199
Total assets000021–510
000021–153
000000–358
Net debt000000–−1
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
0000–2
0000–7
Receivables0000–−194
Payables0000–197
Other working capital0000–5
Capital spending0000–0
Free cash flow0000–2
Cash from investing0010–−1
00−10–0
Dividends paid0000–0
Shares bought back0000–0
Shares issued0000–0
Net change in cash0000–0
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00–−₹0.01–−₹0.04
As stated that year₹0.02−₹0.02₹0.00−₹0.01₹0.05₹0.02–−₹0.13–−₹0.04
₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00–−₹0.01–−₹0.04
––₹0.00₹0.00₹0.01₹0.01₹0.10₹0.09–₹0.79
Shareholder yield––––0.0%0.0%0.0%0.0%–0.0%
Market cap at the year end (₹ crore)5.4–0.70.52.513.25.45.1–29.7
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from. As stated that year and earnings per share are left blank for the year to Mar 2023: the earnings per share is stated as 0 while the period's profit or loss comes to at least half a paisa a share, so the 0 stands in for a figure the filing does not give.
RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Revenue growth−10.0%−44.4%59.0%3.8%61.6%−21.2%−100.0%–––
Operating profit growth–––––−57.0%––––
Net profit growth−67.4%––––−57.2%330.9%–––
Earnings per share growth–––––−60.0%––––
––16.5%−50.0%131.7%29.1%–––−5.5%
–––−66.5 pts181.7 pts−102.6 pts––––
From the net margin–––−55.1 pts229.5 pts−60.1 pts––––
From asset turnover–––−5.3 pts−17.8 pts−39.2 pts––––
From borrowing–––−6.1 pts−30.0 pts−3.3 pts––––
Return on capital employed––9.7%−68.5%79.1%25.4%−8.9%−20.1%–−7.2%
Cash conversion––––76.6%78.4%105.1%–––
Debt to equity––0.000.000.000.000.000.00–0.00
Receivable days––0000–––213
Inventory days–––––––––163
Payable days–––––––––0
Cash conversion cycle, days–––––––––376
Working capital days––404060−13–––143
Asset turnover––2.673.032.731.240.000.00–0.94
Assets per rupee of net worth––1.261.431.171.051.011.02–3.90
Sales per rupee of plant––––––0.000.00–32,931.38
Capital spending to depreciation––––––0.000.00–0.00
Plant being built, % of plant in use––––––0.0%–––
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−1.4%
Measure10 years5 years3 years
Revenue growth, yearly rate127.1%387.1%–
Return on capital employed, average–−2.7%−13.6%
Asset turnover, average–0.540.47
Debt to equity, average–0.000.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations1.74
Cash from investing−1.29
Cash from financing0.00
Capital spending0.00
Dividends paid0.00
Shares bought back0.00
Shares issued for cash0.00
Borrowings raised0.00
Borrowings repaid0.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9––63––––
Altman Z-scorePublished threshold 1.81−493.72−654.60154.091,698.19228.9486.30–0.99
Profit not backed by cash, % of assets––26.436.01−163.09−14.65––
Cash from operations to profit, 3 years––––0.93–––
Other current assets growth less revenue growth–5.454.65−24.29––––
Assets under construction, years of additions––––0.00–––
Effective tax ratePublished threshold 17.16 per cent0.00–0.000.000.00–––
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––0.000.00–––
A threshold marked as ours has no published figure; it is the line we read the check against.